Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR6 | P46095 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410627 | 0.78 | TACR1 (0.53) | TACR1 | |
| SCHEMBL4487177 | 0.77 | TACR1 (0.55) | ALDH1A1TACR1KMT2A | |
| SCHEMBL6410854 | 0.77 | TACR1 (0.55) | TACR1 | |
| SCHEMBL6405890 | 0.74 | KMT2A (0.58) | ALDH1A1LMNATACR1GAAPOLB | |
| SCHEMBL3435702 | 0.74 | ALDH1A1 (0.59) | ALDH1A1ALOX5RAB9ANPC1GAA | |
| SCHEMBL2079194 | 0.74 | ALDH1A1 (0.59) | ALDH1A1ALOX5RAB9ANPC1GAA | |
| SCHEMBL2153249 | 0.72 | TDP1 (0.67) | ALDH1A1ALOX5LMNAGAAPOLB | |
| SCHEMBL30865951 | 0.72 | ALOX5 (0.72) | ALDH1A1ALOX5GAAPOLBKMT2A | |
| SCHEMBL19995957 | 0.71 | NPC1 (0.56) | ALDH1A1ALOX5LMNARAB9ANPC1 | |
| SCHEMBL20006108 | 0.71 | NPC1 (0.56) | ALDH1A1ALOX5LMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | ALDH1A1 1984/4885ALOX5 2580/4885LMNA 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.